Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Yubo International Biotech Ltd

Ticker
YBGJ
Sector
Industry
Report date
November 10, 2026
Valye AI Score

93

Very high visibility
Recent developments
Recent developments summary

Recent news coverage relevant to Yubo International Biotech Ltd centers on macroeconomic factors affecting commodity prices and broader market conditions, providing context for the company’s operating environment.

Recent developments:
  • Brazilian Real weakness and rising Brazil exports have weighed on coffee prices, a factor relevant to the company’s sector environment [N1].
  • Other recent news includes earnings call transcripts from various companies and commodity price movements, reflecting broader economic and market trends [N2][N3][N4][N5][N6][N7][N8].
Overview

Yubo International Biotech Ltd is a publicly traded company with regulatory filings providing insight into its financial condition and regulatory environment. The company reported no revenue and a net loss in the latest quarter, with liquidity ratios indicating limited short-term financial resources. It operates subsidiaries in the PRC and Hong Kong, subject to complex tax and foreign exchange regulations. The company’s auditor is a US-based PCAOB-registered firm, mitigating some audit-related regulatory risks. The company faces risks related to potential delisting under the Holding Foreign Companies Accountable Act if audit inspections are restricted. Foreign exchange controls and PRC tax residency classification uncertainties present additional operational and financial risks. Recent news coverage includes macroeconomic developments impacting commodity prices relevant to the company’s sector.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Yubo International Biotech Ltd reported no revenue and a net loss of $188,376 for the quarter ended September 30, 2026, with liquidity ratios indicating constrained short-term financial flexibility. The company faces regulatory risks related to audit inspections under the Holding Foreign Companies Accountable Act and tax uncertainties stemming from PRC residency classification and withholding tax obligations. Foreign exchange controls and compliance with PRC foreign exchange registration requirements may impact capital flows and dividend distributions. Recent news highlights macroeconomic factors such as Brazilian Real weakness affecting commodity prices relevant to the company’s sector [S2][S1][N1].

Scenarios for YBGJ

Bull case model:

The company benefits from having a US-based PCAOB-registered auditor, which reduces certain regulatory risks related to audit inspections and potential delisting. Its subsidiaries in China and Hong Kong position it to access growing biotech markets, subject to navigating complex tax and foreign exchange regulations. Recent macroeconomic developments such as currency fluctuations and commodity price changes may create opportunities for the company to leverage sector dynamics.

Bear case model:

The company reported no revenue and a net loss in the latest quarter, with liquidity ratios indicating constrained short-term financial flexibility. It faces significant regulatory risks including potential delisting under the Holding Foreign Companies Accountable Act if audit inspections are restricted. Uncertainties around PRC tax residency classification and withholding tax obligations could materially affect financial results. Foreign exchange controls and incomplete compliance by beneficial owners with registration requirements may restrict capital flows and dividend distributions, impacting operational flexibility.

Moat:

The company’s moat is not explicitly disclosed in the available filings or news. However, operating within the biotech sector with subsidiaries in China and Hong Kong, the company faces regulatory and tax complexities that may create barriers to entry for competitors unfamiliar with these environments. The PCAOB-registered auditor status may provide some assurance of audit quality compared to peers audited by firms with limited PCAOB access. The company’s exposure to PRC regulatory and foreign exchange controls may limit competitive pressures but also introduces operational risks.

Risks overview
Risks summary
The most significant risks include potential delisting under the Holding Foreign Companies Accountable Act due to audit inspection issues, and tax and foreign exchange regulatory uncertainties in China that could materially impact financial results and shareholder returns.
Risks details:

• Regulatory Risk under Holding Foreign Companies Accountable Act: If the PCAOB is unable to inspect the company’s auditor due to foreign jurisdiction restrictions, trading in the company’s securities could be prohibited after two consecutive years, potentially leading to delisting and impaired liquidity for shareholders [S1].
• Tax Residency and Withholding Tax Uncertainty: The company faces uncertainty regarding its classification as a PRC resident enterprise for tax purposes. If classified as such, it may be subject to PRC enterprise income tax on global income and withholding taxes on dividends paid to non-resident shareholders, adversely affecting shareholder returns [S1].
• Foreign Exchange and Capital Flow Restrictions: PRC foreign exchange controls limit the convertibility of RMB and the ability to remit funds abroad, which may restrict the company’s ability to pay dividends or satisfy foreign currency obligations. Failure of beneficial owners to comply with SAFE registration requirements may further restrict capital contributions and dividend distributions [S1].
• Liquidity Constraints: As of September 30, 2026, the company’s current ratio was 0.16 and cash ratio was 0, indicating limited short-term liquidity to meet current liabilities, which may affect operational stability [S2].

FINAL FORECAST FOR YBGJ

Final take one line
Yubo International Biotech Ltd exhibits very high visibility due to detailed SEC disclosures and relevant macroeconomic news, highlighting regulatory, tax, and liquidity risks in its operating environment.
Final take 12 to 24 month view

Business trends: The company operates amid complex PRC regulatory and tax environments with macroeconomic factors such as currency fluctuations impacting sector conditions.
Execution milestones: Compliance with PCAOB audit inspection requirements and PRC foreign exchange registration rules remain critical to maintaining listing status and operational flexibility.
Key risks: Potential delisting under the Holding Foreign Companies Accountable Act, PRC tax residency uncertainties, foreign exchange controls, and liquidity constraints pose significant operational and financial risks.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

93
LLM visibility overview
LLM Visibility known facts
  • Yubo International Biotech Ltd is a publicly traded company with ticker YBGJ.
  • The company filed a 10-K annual report on 2026-03-31 and a 10-Q quarterly report on 2026-11-10, providing regulatory and financial disclosures [S1][S2].
  • As of 2026-09-30, the company reported cash and cash equivalents of $11,989 and current assets of $579,352, with current liabilities of $3,549,427, resulting in a current ratio of 0.16 and a cash ratio of 0, indicating liquidity constraints [S2].
  • The company reported zero revenue and a net loss of $188,376 for the quarter ending 2026-09-30 [S2].
  • The company’s auditor is HCL PLLC, a US-based independent registered public accounting firm subject to PCAOB inspections, which reduces certain regulatory risks related to audit quality [S1].
  • The company is subject to risks related to the Holding Foreign Companies Accountable Act, including potential delisting if audit inspections are restricted [S1].
  • Yubo International Biotech Ltd has subsidiaries in the PRC and Hong Kong, with dividend payments potentially subject to PRC withholding tax rates ranging from 5% to 20%, depending on tax residency and treaty status [S1].
  • The company is not currently classified as a PRC resident enterprise for tax purposes but faces uncertainty as PRC tax authorities may determine otherwise, which could materially affect tax liabilities and shareholder returns [S1].
  • Foreign exchange controls and RMB convertibility restrictions in China may limit the company’s ability to transfer funds and pay dividends in foreign currency [S1].
  • The company’s beneficial owners who are PRC residents may be subject to registration requirements under SAFE Circular 37, and failure to comply may restrict capital contributions and dividend distributions [S1].
  • Recent business news relevant to the company’s operating environment includes reports on Brazilian Real weakness and its impact on coffee prices, which may affect related agricultural or biotech sectors [N1].
  • Additional recent news includes broader market and sector developments such as earnings call transcripts from other companies and commodity price movements, providing context for the economic environment [N2][N3][N4][N5][N6][N7][N8].
Sources
Sources - Context summary

Generated 2026-11-10

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-31 | 10-K
  • S2 | 2026-11-10 | 10-Q
Sources - News headlines
  • N1 | 2026-11-10 | www.nasdaq.com | Brazilian Real Weakness and Rising Brazil Exports Weigh on Coffee Prices | https://www.nasdaq.com/articles/brazilian-real-weakness-and-rising-brazil-exports-weigh-coffee-prices
  • N2 | 2026-11-10 | www.nasdaq.com | Fossil Swings To Q3 Profit, Raises Full-Year 2026 Outlook | https://www.nasdaq.com/articles/fossil-swings-q3-profit-raises-full-year-2026-outlook
  • N3 | 2026-11-10 | www.nasdaq.com | NH Investors (NHI) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/nh-investors-nhi-q3-2026-earnings-call-transcript
  • N4 | 2026-11-10 | www.nasdaq.com | Kemper (KMPR) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/kemper-kmpr-q3-2026-earnings-call-transcript
  • N5 | 2026-11-10 | www.nasdaq.com | Stocks Retreat as Price Pressures Push Bond Yields Higher | https://www.nasdaq.com/articles/stocks-retreat-price-pressures-push-bond-yields-higher
  • N6 | 2026-11-10 | www.nasdaq.com | Grupo Cibest (CIB) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/grupo-cibest-cib-q3-2026-earnings-call-transcript
  • N7 | 2026-08-17 | www.nasdaq.com | Wheat Rallying as Russia Rejects Ukraine’s Proposal | https://www.nasdaq.com/articles/wheat-rallying-russia-rejects-ukraines-proposal
  • N8 | 2026-08-17 | www.nasdaq.com | Fortinet Acquires Virtue AI For Undisclosed Terms | https://www.nasdaq.com/articles/fortinet-acquires-virtue-ai-undisclosed-terms
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine